BioCardia, Inc. (NASDAQ:BCDA – Get Free Report) was the recipient of a large decrease in short interest in January. As of January 15th, there was short interest totalling 50,400 shares, a decrease of 39.6% from the December 31st total of 83,400 shares. Currently, 1.3% of the shares of the stock are short sold. Based on an average daily trading volume, of 48,500 shares, the days-to-cover ratio is currently 1.0 days.
BioCardia Price Performance
BCDA stock traded down $0.06 during trading on Thursday, reaching $2.32. 23,617 shares of the stock traded hands, compared to its average volume of 46,464. The business’s 50 day moving average price is $2.20 and its 200-day moving average price is $2.52. The firm has a market capitalization of $10.63 million, a PE ratio of -0.55 and a beta of 1.26. BioCardia has a 52-week low of $1.63 and a 52-week high of $8.85.
Analysts Set New Price Targets
Separately, HC Wainwright reiterated a “buy” rating and set a $25.00 price objective on shares of BioCardia in a research report on Wednesday, December 18th.
About BioCardia
BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.
Further Reading
- Five stocks we like better than BioCardia
- What is the Euro STOXX 50 Index?
- How Growth Investors Find High-Growth Stocks and Maximize Returns
- How Investors Can Find the Best Cheap Dividend Stocks
- Meta’s AI & Smart Glasses Could Drive 20%+ Upside in 2025
- What is Forex and How Does it Work?
- NVIDIA’s Slide Continues: Can Retail Investors Stop the Fall?
Receive News & Ratings for BioCardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCardia and related companies with MarketBeat.com's FREE daily email newsletter.